Gland Pharma Ltd Q1 FY27 Earnings Call: Guides ~20% CAGR Over Four Years, GLP-1 CDMO Guides 50% Growth

Gland Pharma Ltd held its Q1 FY27 earnings call on August 10, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Strong Start to FY27 with 20% Revenue Growth

• Q1 FY 2026-2027 revenue at Rs.18,003 million — up 20% YoY, driven by CDMO and B2B momentum, product launches, and volume growth across segments.
• Adjusted EBITDA at Rs.5,102 million — margin of 28%, up from 25% in Q1 FY 2025-2026; gross margin improved to 65% aided by favorable product mix and higher CDMO contribution.
• PAT at Rs.3,170 million, up 47% YoY — PAT margin of 18%; sequentially lower due to a Rs.36 million forex loss vs a Rs.508 million forex gain in Q4 FY 2025-2026.
• R&D spend at Rs.772 million (~4% of revenue) — up 16% YoY, focused on complex injectables, peptides, depot products, and liposomal platforms.
• Total cash and cash equivalents at Rs.35,466 million — net cash position of Rs.32,939 million; operating cash flow of Rs.3,183 million in the quarter.
• Launched 4 products in the US during Q1 — filed 3 ANDAs and received 7 approvals during the quarter.

Revised Growth Outlook and Major Contract Wins

• Growth target revised to ~20% CAGR over four years — management now "expects ~20% growth over the next four years (FY 2027-2028 to FY 2030-2031)," driven by a new contract covering ~12% of current revenue; more clarity expected in Q2 FY 2026-2027.
• Strategic manufacturing agreement for 55 SKUs — signed with a specialty pharma global company; portfolio includes oncology and non-oncology products across formats; peak revenue potential ~$90-$100 million, with ramp-up from CY2029 to CY2030.
• GLP-1 CDMO segment guided at 50% constant currency growth for FY 2026-2027 — new contract signed in Q1 for semaglutide and tirzepatide targeting US and EU markets; potential upside from Canada launch in Q4 FY 2026-2027.
• In-licensing agreement with China-based firm for a niche liposomal product — rights for US and Europe; management cited "commercial opportunities from FY30"; global market estimated at $3 billion over the next 3 years.
• Collaboration with Newland Laboratories for sterile APIs — focused on micro-particle depot products; API suite expansion driven by capacity constraints and Gland's own pipeline of 5-6 products.
• Biologics partnership with Dr. Reddy's generating Rs.50-60 crores annually — run-rate as of Q1 FY 2026-2027; expected to ramp up slowly from FY 2027-2028 onwards.

Margin Expansion Path and Capacity Investments

• Near-term target of 30% EBITDA margin — consolidated, up from 28% in Q1 FY 2026-2027; medium to long-term aspiration of "35% EBITDA margin within the next three to four years, likely by CY2029," contingent on CDMO contracts scaling up.
• CDMO contributed ~50% of business in Q1 — near-term target is a balanced 50-50 split between CDMO and B2B over the next two years.
• FY 2026-2027 capex guidance at ~Rs.550 crores — includes Rs.165 crore for an oncology plant (installation planned by January FY 2027), Newland API collaboration investment, and a new BFS/ophthalmic line at Pashamylaram.
• Multi-year Rs.2,000 crore capex program underway — covering vial, ophthalmic, PFS, and lyo lines at Indian sites, plus new vial/lyo block at Senexi's BLA site and a high-speed ampoule line at Fontenay on track for completion by end of FY 2027-2028.
• New high-capacity ampoule line at Fontenay — will add 30 million units annual capacity, with expected production in early 2027.
• Profit share for Q1 FY 2026-2027 was 9% — new CDMO contract's commercialized portion (sourced from high-cost US/Europe manufacturing) offers better margin profile than IP-owned business where profits are shared with front-end partners.

US Leads Growth; Complex Pipeline Takes Shape

• US revenue at Rs.9,810 million, up 32% YoY — driven by recent CDMO launches and volume expansion; US base revenue annualized run rate ~$110 million as of Q1 FY 2026-2027; management expects US growth to significantly outpace market growth of 3-4%.
• Europe & other regulated markets revenue at Rs.4,488 million, up 11% YoY — ROW revenue at Rs.3,039 million, flat YoY, impacted by supply disruption in Saudi Arabia due to delayed Nupco tenders.
• Synexy (CDMO Europe) generated €48M revenue and €2M EBITDA in Q1 — implied ~4.2% margin; management targets double-digit EBITDA by end of FY 2026-2027, with full-year guided at 4% EBITDA.
• Complex ANDA pipeline of 20-25 products — includes several large microsphere opportunities; most major launches expected after FY 2028-2029.
• CDMO pipeline includes 15 products — 7 505(b)(2) and 8 NDAs — awaiting market launch; 4 products launched in Q1 including multivitamin (MVI), Dalba, and Sugammadex; MVI has CGT exclusivity with no immediate competition.
• Base business ex-NXC grew 24% in Q1 FY 2026-2027 — US market grew 32% in the same quarter; constant currency growth for base business was 19-20%, after removing an estimated 5% forex gain.

FY27 Guidance and Key Uncertainties

• FY 2026-2027 constant currency revenue growth guided at 15% (base case) — approval of new bag line in Q3 FY 2026-2027 (potential FDA clearance as early as August-September 2026) could lift growth above 15%; all future guidance provided on constant currency basis.
• Cenexi guidance maintained at ~€200 million revenue and high single-digit margin for FY 2026-2027 — Q2 expected better than prior year as shipments delayed from Q1 (heatwave in France impacting quality release) shift into Q2.
• GLP-1 revenue over next three years (FY 2027-2028 to FY 2029-2030) expected to be "very limited" — primarily from tech transfer fees; "significant volume is not anticipated until FY 2030-2031" when US approvals materialize.
• NDDS project timeline set — development by FY28 (ending March 2028) and commercialization by FY29 (ending March 2029), with targeted revenue potential of $25-30 million.
• Capacity constraints on bag line and ophthalmic products persist; bag line requires FDA approval; additional brownfield/greenfield capacity under evaluation.
• CDMO business currently has no innovator products under supply; pipeline discussions ongoing but not yet signed, related to peptide side (not small molecule or bio CDMO).
• Key risk: As a CDMO business, management lacks clear visibility on customers' front-end approval timelines in other markets.